atorvastatin has been researched along with Coronary Restenosis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q | 1 |
| Guo, J; Li, T; Liu, Y; Yao, Y; Zeng, Z; Zhang, R; Zhao, Y | 1 |
| Chello, M; Coccia, R; Covino, E; De Marco, F; Di Domenico, F; Di Sciascio, G; Lusini, M; Patti, G; Pettinari, M; Pollari, F; Spadaccio, C; Zanzonico, R | 1 |
| Buszman, P; Cybulski, W; Dworowy, S; Jadczyk, T; Kawecki, D; Król, M; Milewski, K; Ochała, A; Pawłowski, T; Pyrlik, A; Rudnik, A; Smolka, G; Tendera, M; Wojakowski, W; Wyderka, R | 1 |
| Czechowska, M; Goracy, J; Kaliszczak, R; Kaźmierczak, J; Kornacewicz-Jach, Z; Lewandowski, M; Millo, B; Naruszewicz, M; Płońska, E; Zielonka, J | 1 |
| Chen, BY; Deng, CQ; Li, H; Tang, YH; Wu, L; Zhang, GM; Zhang, W | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK | 1 |
| Benit, E; Channon, KM; de Winter, RJ; den Dekker, WK; den Heijer, P; Duckers, HJ; Grisold, M; Hill, J; Houtgraaf, JH; Ligtenberg, E; Onuma, Y; Rensing, BJ; Rowland, SM; Serruys, PW; Silber, S; Teiger, E; Verheye, S; Wiemer, M; Wijns, W | 1 |
| Böhm, M; Nickenig, G; Scheller, B; Schmitt, A | 1 |
| Hartmann, M; von Birgelen, C | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Altinbas, A; Aslan, SM; Dede, O; Dogan, A; Ozaydin, M; Ozturk, M; Turker, Y; Varol, E | 1 |
| Chyrchel, M; Dubiel, JS; Dudek, D; Dziewierz, A; Legutko, J; Rakowski, T; Rzeszutko, L | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Billinger, M; Cook, S; Haeberli, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Erl, W | 1 |
| Guan, X; Sun, ZS; Zhou, SH | 1 |
| Barter, P; Breazna, A; DeMicco, DA; Kastelein, JJ; LaRosa, JC; Shah, SJ; Shepherd, J; Waters, DD; Wenger, NK | 1 |
1 review(s) available for atorvastatin and Coronary Restenosis
| Article | Year |
|---|---|
Intravascular ultrasound assessment of coronary atherosclerosis and percutaneous interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Heptanoic Acids; Humans; Pyrroles; Stents; Treatment Outcome; Ultrasonography, Interventional | 2004 |
8 trial(s) available for atorvastatin and Coronary Restenosis
| Article | Year |
|---|---|
Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coated Materials, Biocompatible; Coronary Restenosis; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Radiography; Risk Factors; Stem Cells; Stents; Treatment Outcome | 2013 |
The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Angiography; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Probability; Pyrroles; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Cell Movement; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Disease-Free Survival; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Stem Cells; Stents; Treatment Outcome | 2011 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Chronotherapy; Coronary Restenosis; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Prosthesis Failure; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2007 |
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Female; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
9 other study(ies) available for atorvastatin and Coronary Restenosis
| Article | Year |
|---|---|
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Humans; Metformin; Percutaneous Coronary Intervention; Risk Factors; Sirolimus; Stents; Treatment Outcome | 2022 |
Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Restenosis; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium; Gene Expression Regulation; Humans; Inflammation; Interleukin-1; Interleukin-12; Interleukin-6; Interleukin-8; NF-kappa B; Rabbits; Tumor Necrosis Factor-alpha | 2018 |
Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
Topics: Aged; Angina, Stable; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Restenosis; Diabetes Complications; Drug-Eluting Stents; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Tubulin Modulators | 2013 |
Effect of total saponins of "panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Cell Cycle Proteins; Collagen Type I; Coronary Restenosis; Cyclins; Drugs, Chinese Herbal; Extracellular Matrix; Fibronectins; Heptanoic Acids; Hyperplasia; Male; Matrix Metalloproteinase 9; Panax notoginseng; Phytotherapy; Plant Roots; Proliferating Cell Nuclear Antigen; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Tissue Inhibitor of Metalloproteinase-1; Tunica Intima | 2010 |
Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting.
Topics: Administration, Topical; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Atorvastatin; Cell Division; Cell Movement; Coated Materials, Biocompatible; Coronary Restenosis; Coronary Vessels; Heptanoic Acids; Muscle, Smooth, Vascular; Pyrroles; Stents; Swine | 2003 |
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Premedication; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2006 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
Atorvastatin-induced downregulation of survivin and vascular smooth muscle cell apoptosis: a causal relationship in restenosis?
Topics: Animals; Apoptosis; Atorvastatin; Coronary Restenosis; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Neoplasm Proteins; Pyrroles; Survivin | 2007 |
Impact of blood circulation on reendothelialization, restenosis and atrovastatin's restenosis prevention effects.
Topics: Angioplasty, Balloon, Coronary; Animals; Atorvastatin; Carotid Arteries; Coronary Circulation; Coronary Restenosis; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats | 2008 |